# US 2019/0315748 A1 · Purinone derivative hydrochloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315748 A1
- Document ID: US20190315748A1
- Status: Published application
- Kind: A1
- Application number: 16/451,538
- Filed: 2019-06-25
- Published: 2019-10-17
- Earliest claimed: 2011-11-29
- Assignees: Ono Pharmaceutical Co., Ltd.
- Applicants: Ono Pharmaceutical Co., Ltd.
- Inventors: Shingo YAMAMOTO; Toshio YOSHIZAWA
- Web page: https://patentgrep.com/patent/US20190315748A1

## CPC

- C07D 473/34: attached in position 6, e.g. adenine
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 473/00: Heterocyclic compounds containing purine ring systems
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A pharmaceutical composition comprising a hydrochloride salt of the compound of the following formula:

### Claim 15

A pharmaceutical composition comprising a hydrochloride salt of the compound the following formula:
and a pharmaceutically acceptable excipient.

### Claim 16 (depends on 14)

The pharmaceutical composition according to claim 14, which is a BTK inhibitor.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, which is a prophylactic agent and/or a therapeutic agent for a Btk-related disease.

### Claim 18 (depends on 17)

The pharmaceutical composition according to claim 17, wherein the Btk-related disease is an allergic disease, an autoimmune disease, an inflammatory disease, a thromboembolic disease, or a cancer.

### Claim 19 (depends on 18)

The pharmaceutical composition according to claim 18, wherein the cancer is a non-Hodgkin's lymphoma.

### Claim 20 (depends on 15)

The pharmaceutical composition according to claim 15, which is a BTK inhibitor.

### Claim 21 (depends on 20)

The pharmaceutical composition according to claim 20, which is a prophylactic agent and/or a therapeutic agent for a Btk-related disease.

### Claim 22 (depends on 21)

The pharmaceutical composition according to claim 21, wherein the Btk-related disease is an allergic disease, an autoimmune disease, an inflammatory disease, a thromboembolic disease, or a cancer.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22, wherein the cancer is a non-Hodgkin's lymphoma.
